Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization

Since the emergence of SARS-CoV-2 (SARS-2), multiple vaccine candidates were developed and studied both preclinically and clinically. Nearly all are based on the SARS-2 spike glycoprotein or its receptor binding domain (RBD). Studies of these vaccine candidates have largely been in a SARS-2 naïve co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Blake M., Sangesland, Maya, Lam, Evan C., Feldman, Jared, Balazs, Alejandro B., Lingwood, Daniel, Schmidt, Aaron G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386501/
https://www.ncbi.nlm.nih.gov/pubmed/35990628
http://dx.doi.org/10.3389/fimmu.2022.902260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386501/
https://www.ncbi.nlm.nih.gov/pubmed/35990628
http://dx.doi.org/10.3389/fimmu.2022.902260

Ejemplares similares